News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Array BioPharma, Inc. (ARRY) Shares Rise on Lung Cancer, Melanoma Results



5/17/2012 7:18:15 AM

BOULDER, Colo., May 16, 2012 (BUSINESS WIRE) -- Array BioPharma Inc. today announced oral presentations on its two MEK inhibitors, selumetinib (AZD6244) and MEK162 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will held June 1-5, 2012 at McCormick Place in Chicago, Illinois. Array invented selumetinib and MEK162 and subsequently licensed them to AstraZeneca and Novartis, respectively.

Three oral presentations at ASCO: Selumetinib

Title: Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC) (Abstract #7503)

Presenter: Pasi A. Janne, MD, PhD

Date: Monday, June 4, 2012, 5:00 - 5:15 p.m. EDT

Title: Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib (Abstract #5509)

Presenter: Alan L. Ho, MD, PhD

Date: Monday, June 4, 2012, 1:00 - 1:15 p.m. EDT

MEK162

----------

Title: Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations* (Abstract #8511)

Presenter: Paolo A. Ascierto, MD

Date: Monday, June 4, 2012, 4:45 - 5:00 p.m. EDT

The abstracts can be accessed through the ASCO website, http://abstract.asco.org/ . After June 4, 2012, the oral presentation slides will be available as PDFs on Array's website at www.arraybiopharma.com .

*The abstract submitted for MEK162 does not incorporate data and new findings generated since the time of submission in early 2012. The latest and most up-to-date clinical data will be delivered during the investigator's presentation at the Annual Meeting itself, at the date and time listed above.

In addition, the following scientific posters on selumetinib and GDC-0068, an Akt inhibitor partnered with Genentech, will be presented at the conference.

SOURCE: Array BioPharma

Array BioPharma Inc.

Tricia Haugeto, 303-386-1193

thaugeto@arraybiopharma.com


Read at Reuters
Read at BioSpace.com
Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES